The method of producing mielopid

 

(57) Abstract:

The invention relates to medicine, namely to methods of producing biologically active preparations from bone marrow of animals. The method includes preparing a suspension of bone marrow cells, their incubation in a nutrient medium, separating the supernatant and the subsequent allocation of a target product, for suspension and incubation of the cells using an empty environment, and the selection of the target product is carried out by passing the supernatant through a biospecific sorbent Adam and extraction of adsorbed material 50-80% solution of ethanol in 0.1% aqueous acetic acid solution. The composition of the preferred option nutrient medium. The method allows to increase the yield of the target product while simplifying the manufacturing processes and reduce labor costs. 1 C.p. f-crystals, 1 table.

The invention relates to a technology for obtaining an immunomodulating drug from the bone marrow of animals.

A known method of producing Mielopid, comprising preparing a suspension of bone marrow cells into a colored 199 environment, their incubation in the same environment, the separation of the supernatant and the allocation of money is eriley water, sterile filtration and gel chromatographic separation on Sephadex G-25 using phosphate buffer (EN 2041716 C1, 20.08.1995).

The disadvantages of this method are the high complexity and the complexity of the technology associated with the need for purification of the target product from the one used suspendirovanie and incubation of the cells of the dye phenol red, part 199 medium, and low yield of the target product, forming 250-300 doses of 1·1010cells.

The technical result of the invention is to reduce labor costs, the simplification of technology and the increase of the yield of the target product.

This result is achieved in that in the method of producing Mielopid, comprising preparing a suspension of bone marrow cells, their incubation in a nutrient medium, separating the supernatant and the subsequent allocation of a target product, according to the invention for the suspension and incubation of the cells using an empty environment, and the selection of the target product is carried out by passing the supernatant through a biospecific sorbent Adam and extraction of adsorbed material with an aqueous solution of ethyl alcohol into acetic acid.

Priya and incubation environment, containing the following components (mg/DM3:

CaCl2200

Fe(NO3)2·9H2O 0,1

KCl 400

MgSO4·7H2O 200

NaCl 6800

NaHCO32200

NaH2PO4·H2O 140

Adenine 10

Sodium salt of denitrificate 10

Denisova acid 0,2

Cholesterol 0,2

2-deoxyribose 0,5

Glucose 1000

Glutathione 0,05

Guanine chloride 0,3

Gipoksantin 0,3

Ribose 0,5

Sodium acetate 50

Thymine 0,3

Twin 80 20

Uracil 0,3

Xanthine 0,3

DL-alanine 50

L-arginine chloride 70

DL-aspartic acid 50

L-cysteine chloride of 0.1

L-cystein 20

L-glutamine 100

DL-glutamic acid·H2O 150

Glycine 50

L-histidine chloride 20

L-hydroxyproline 10

DL-isoleucine 40

DL-leucine 120

L-lysine chloride 70

DL-phenylalanine 50

DL-methionine 50

L-Proline 40

DL-serine 50

DL-threonine 60

DL-tryptophan 20

L-tyrosine 40

DL-valine 50

p is

Choline chloride 0,5

Folic acid is 0.01

i-Inositol 0,05

Menadione 0,01

Nicotinamide 0,025

Nicotinic acid 0,025

Sodium salt of Pantothenic acid 0.01

Pyridoxal chloride 0,025

Pyridoxine chloride 0,025

Riboflavin 0,01

Thiamine chloride in 0.01

p-tocopherolacetate sodium 0,01

Vitamin a IS 0.1

Another preferred option is provided the use of 50-80% ethanol in 0.1% aqueous acetic acid solution.

The method is implemented as follows.

Bone marrow cells extracted from crushed animal bones by suspension in a liquid unpainted environment with subsequent filtering, centrifugation and dilution unpainted nutrient medium containing a mixture of vitamins, amino acids and components of nucleic acids in salt Hanks solution, preferably in the above mixing ratio. Then carry out incubation of cells with the traditional parameters of the process and separate the supernatant by centrifugation. From the supernatant produce the target product by its adsorption on biospecific sorbent Adam (IDT with the concentration of ethyl alcohol 50-80% by volume in 0.1% by volume aqueous solution of acetic acid. Using the above composition of the extractant minimizes its consumption, subsequent labor and energy costs on the selection of the target product and the loss of its active components, which increases the yield of the target product.

Example 1.

8 kg tipped rib bones of pigs crushed in sterile conditions. They added 3 l of sterile liquid nutrient medium of the above composition. The suspension is shaken on a shaker at C for 1 hour to flush the bone marrow cells. Cells separated by filtration and washed by centrifugation in the same nutrient medium at 4C. The obtained cells are diluted with the same medium, bringing their concentration up to 1·109cells/DM3and incubated for 18-20 hours at S. Next, separate the supernatant by centrifugation at 5000 rpm and a temperature of 4C. The supernatant is passed through a column Packed with biospecific sorbent Adam. The adsorbed material is extracted with 6S, using as extractant 50-80% solution of ethanol in 0.1% aqueous acetic acid solution. At concentrations above this extraction does not occur. At concentrations below this dramatically increases the flow of extractant that when posleduyu activity of the drug. The product yield factor stimulation 1,8 ranges from about 40,000 doses of the drug with the boundary values of the concentration of the extractant to 50,000 at a concentration of ethyl alcohol in the extractant 60% by volume.

The biological effect of the target product is estimated by the stimulation of antibody productions at the peak of the secondary immune response to sheep erythrocytes (Jerne, N. K., Nordin A. A.// Science, 1983, v. 140, p. 405), by adding the test material in the cell culture of lymph nodes obtained from mice on the fourth day after the second immunization. The stimulation coefficient calculated as the ratio of the number of antibody productive cells (AFC) in the culture with the test sample to the amount of the KLA in control. The results are given in the table.

Thus, when simplified technology and reduced labor costs, the proposed method allows to increase the output of Mielopid.

Example 2.

The product prepared according to example 1, but using a nutrient medium containing the following components (mg/DM3:

CaCl2200

Fe(NO3)3·N2O 0,1

KCl 400

MgSO4·7H2O 200

NaCl 5400

Panso33700

< A CLASS="ptx2">

L-arginine chloride 84

L-cystein 48

L-glutamine 780

Glycine 30

L-histidine chloride water 42

L-isoleucine 105

L-leucine 105

L-lysine chloride 146

L-methionine 30

L-phenylalanine 86

L-serine 42

L-threonine 85

L-tryptophan 18

L-tyrosine 72

L-valine 94

Choline chloride 4

Folic acid 4

i-Inositol 7,2

Nicotinamide 4

Sodium salt of Pantothenic acid 4

Pyridoxal chloride 4

Riboflavin 0,4

Thiamine chloride 4

The product yield factor stimulation 1,8 ranges from 20000 to 32000 doses of the drug at various concentrations of ethanol in the extractant.

Example 3.

The product prepared according to example 1, but using a nutrient medium containing the following components (mg/DM3:

CA(NO3)2·4H2O 100

KCl 400

gSO4·7H2O 100

NaCl 6000

NaHCO32000

Na2HPO4801

Glucose 2000

Glutathione 1

Garamycin 15

L-arginine chloride 342

L-asparagine 50

Glycine 10

L-histidine chloride 18,2

L-hydroxyproline 20

L-isoleucine 50

L-leucine 50

L-lysine chloride 50

L-methionine 15

L-phenylalanine 15

L-Proline 20

L-serine 30

L-threonine 25

L-tryptophan 5

L-tyrosine 20

L-valine 20

p-aminobenzoic acid 1

Biotin 0,2

Choline chloride 3

folic acid 1

i-Inositol 36

Nicotinamide 1

Sodium salt of Pantothenic acid 0,75

Pyridoxal chloride 1

Riboflavin 0,2

Thiamine chloride 1

Vitamin B120,008

The product yield factor stimulation 1,8 ranges from 12000 to 25000 doses of the drug at various concentrations of ethanol in the extractant.

1. The method of producing Mielopid, comprising preparing a suspension of bone marrow cells, their incubation in a nutrient medium, separating the supernatant and the subsequent allocation of a target product, characterized in that the suspension and incubation of the cells using an empty environment, and the selection of the target product is carried out by passing the supernatant is alcohol in 0.1% aqueous solution of acetic acid.

2. The method according to p. 1, characterized in that the suspension and incubation of bone marrow cells using a medium containing the following components (mg/DM3:

l2200

Fe(NO3)2·9H2O 0,1

KCl 400

MgSO4·7H2O 200

NaCl 6800

NaHCO32200

NaH2PO4·H2O 140

Adenine 10

Sodium salt of denitrificate 10

Denisova acid 0,2

Cholesterol 0,2

2-Deoxyribose 0,5

Glucose 1000

Glutathione 0,05

Guanine chloride 0,3

Gipoksantin 0,3

Ribose 0,5

Sodium acetate 50

Thymine 0,3

Twin 80 20

Uracil 0,3

Xanthine 0,3

DL-alanine 50

L-arginine chloride 70

DL-aspartic acid 50

L-cysteine chloride of 0.1

L-cystein 20

L-glutamine 100

DL-glutamic acid·N2About 150

Glycine 50

L-histidine chloride 20

L-hydroxyproline 10

DL-isoleucine 40

DL-leucine 120

L-lysine chloride 70

DL-phenylalanine 50

DL-methionine 50

L-Proline 40

p-Aminobenzoic acid 0,05

Ascorbic acid is 0.05

Biotin 0,01

Calciferol 0,1

Choline chloride 0,5

Folic acid is 0.01

i-Inositol 0,05

Menadione 0,01

Nicotinamide 0,025

Nicotinic acid 0,025

Sodium salt of Pantothenic acid 0.01

Pyridoxal chloride 0,025

Pyridoxine chloride 0,025

Riboflavin 0,01

Thiamine chloride in 0.01

p-Tocopherolacetate sodium 0,01

Vitamin A Is 0.1

 

Same patents:

The invention relates to medicine, namely to Oncology, and can be used for the treatment of patients with malignant tumors of the organs of the oral cavity and pharynx
The invention relates to medicine, and is intended for the treatment of peritonitis

The invention relates to medicine, namely to Oncology, and can be used to treat cancer of the larynx

The invention relates to medicine, namely to Oncology, and can be used in cancer chemotherapy breast cancer stage III-IV
The invention relates to medicine, namely to traumatology and orthopedics, and can be applied to accelerate the fusion of the bone fragments
The invention relates to medicine, namely to methods of producing biologically active substances from natural raw materials

The invention relates to animal health, to the prevention of leukemia in cattle
The invention relates to medicine, namely to methods for treatment and prevention of immunologic deficiency
The invention relates to medicine, in particular to addiction

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves using mononuclear autologic marrow fraction containing 6-9x104 mesenchyma cells per 1 ml or autologic mesenchyma trunk cells. The cells are separated from brain bioptate in the amount of 106 cells/kg of patient body mass. The preparations are intracoronarily introduced in fractions at a rate of 3-5 ml/min into the right coronary artery. The introduction is also carried out in intra-arterial mode in jets or in drops.

EFFECT: higher survival rate and life quality of cardiologic patients.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing autologic mesenchyma trunk cells as a single intravenous drop dose or in the amount of 1 mln cells per 1 kg of patient body weight.

EFFECT: provided stable clinical remission.

FIELD: medicine, surgery.

SUBSTANCE: method involves every day covering a wound with an agent comprising of pig spleen homogenate and oxygenated with perfluorane taken in the following amounts: 100 g of pig spleen homogenate and 10 ml of oxygenated perfluorane. Invention promotes to accelerating sanitation of suppurative wounds due to activation of topical immunity and activation of regenerating processes. Invention can be used in treatment of suppurative wounds.

EFFECT: improved treatment method of wounds.

2 ex

FIELD: medicine, oncourology.

SUBSTANCE: the present innovation deals with treating locally spread tumor diseases of urinary bladder due to applying either chemo- and/or radiation therapy. Moreover, one should intravenously once inject by drops autologous mesenchymal stem cells (AMSC) at the quantity of 1 mln cells/kg patient's body weight. Moreover, in case of chemotherapy AMSC should be injected during the period before the 20-th d after the last injection of chemopreparation, in case of radiation therapy - 12-15 d against the day of irradiation. In case of chemoradiation therapy AMSC should be injected after chemotherapy before the course of radiation therapy. This method enables to carry out chemoradiation therapy in patients with severe accompanying diseases that prevent such a therapy, and prevent the development of general toxic complications of chemoradiation therapy and medicinal and radiation-caused cystitis.

EFFECT: higher efficiency of therapy.

3 ex, 2 tbl

FIELD: medicine; medical engineering.

SUBSTANCE: biotransplant has genetically unmodified mesenchyma stem cell culture as active component obtained from fetal donor autologous material. The tissue is subjected to disaggregation and the produced cell suspension is resuspended and cultivated on growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulate mature stroma in cell culture. Method involves intravenously dropping mesenchyma stem cell culture in the amount of 50 to 500 mln in 50-100 ml of physiologic saline.

EFFECT: accelerated recovery of bone tissue; positive biochemical factors dynamics; improved patient locomotor activity.

6 cl

FIELD: medicine; medical engineering.

SUBSTANCE: biotransplant has genetically unmodified mesenchyma stem cell culture as active component obtained from fetal donor autologous material and genetically unmodified fetal myoblast culture. Method involves intravenously dropping mesenchyma stem cells in the amount of 50 to 500 mln in 50-100 ml of physiologic saline. The fetal myoblast culture is intramuscularly introduced at a dose of 100 mln of cells per 10 kg.

EFFECT: enhanced effectiveness in repairing incretory function of pancreas and reducing resistance to insulin; reduced risk of nephropathy and other complications.

9 cl

FIELD: medicine, cardiology.

SUBSTANCE: one should introduce the suspension of autologous mononuclear medullary cells without preliminary cultivation in to the mouth of coronary artery nourishing infarction area. Cell suspension should be introduced at the quantity of 100-150 mln. cells immediately after stenting coronary artery due to technique of passive passage. The procedure should be performed on the 14th - 21st d against the onset of the disease mentioned. The method provides efficient counterbalance of cardiomyocytes due to applying valuable stem cells at excluding complications induced by arterial occlusion.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

FIELD: medicine, in particular hematology.

SUBSTANCE: CBA/CaLac intact mouse spleen is homogenized in medium containing 95 % of RPMI-1640 and 5 % of ethyl silicate; filtered through nylon grid; washed by centrifugation with RPMI-1640. at 1500 rpm for 10-15 min; final concentration of living splenocites is adjusted to 2x106 colony/ml using media containing 10 % of ethyl silicate, 1 % of L-glutamine; 0.2 % of gentamycine, 0.05 % of mercaptoethanol, 89 % of RPMI-1640; obtained product is cultivated at 37°C for 6 days, centrifuged and supernatant containing target product is separated followed by storage at -20°C. Before filtering 1 ml of distilled water is added in sterile spleen homogenate and after 25 sec 10 ml of RPMI-1640 medium is added. Target product is stored for 1 month or less.

EFFECT: method of improved accuracy and validity.

1 tbl

FIELD: medicine, in particular uses of viruses for cell elimination.

SUBSTANCE: invention relates to uses of viruses capable of reducing undesired cells in ex vivo mixtures of normal marrow or peripheral blood cells and tumor cells, such as leucosis or lymphoma cells due to interaction of abovementioned mixture with vesicular stomatitis virus. Invention also relates to method for malignant tumor treatment in mammalian. Claimed method includes sampling of mammalian marrow or peripheral blood cells; interaction of said cells ex vivo with vesicular stomatitis virus; mieloablative therapy; and transplantation of purified hematopoietic cells into mammalian. In another embodiment invention relates to method for malignant tumor treatment in mammalian having transplant of marrow or peripheral blood stem cells. Said method includes interaction ex vivo of collected transplant cell with vesicular stomatitis virus and administration of these purified cells in mammalian. Method of present invention makes it possible to reduce risk of malignant tumor backset in mammalian with transplanted hematopoietic cells.

EFFECT: new agent for elimination of marrow or peripheral blood tumor cells.

12 cl, 4 ex, 3 tbl

Up!